Literature DB >> 31251821

Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban.

Ifeoma Mary Eche1, Pansy Elsamadisi1, Nicole Wex1, Mark C Wyers2, Gabriel A Brat3, Katherine Cunningham1, Kenneth A Bauer4.   

Abstract

The authors describe a case of unfractionated heparin (UFH) unresponsiveness in the operating room secondary to reversal of rivaroxaban with coagulation factor Xa (recombinant) inactivated-zhzo (andexanet alfa). A 70-year-old man with a known 4.5- to 5.0-cm abdominal aortic aneurysm and atrial fibrillation managed with rivaroxaban presented with severe right-sided flank pain radiating to the left side of his abdomen. Computed tomography-angiography on arrival demonstrated a left retroperitoneal hematoma and a suspected ruptured abdominal aortic aneurysm. He received andexanet alfa to reverse rivaroxaban prior to an emergent endovascular aneurysm repair. During surgery, he received a total of 14,000 units (167 units/kg) of UFH with minimal changes in activated clotting time (132-144 sec; baseline 135 sec [reference range 74-137 sec]). This case highlights the potential complications of using UFH anticoagulation following reversal of factor Xa inhibitors with andexanet alfa and underscores the importance of peri-procedural anticoagulation planning. For patients who require intra-operative anticoagulation, providers should consider anticoagulation reversal with prothrombin complex concentrate instead of andexanet alfa or administration of a parenteral direct thrombin inhibitor, such as argatroban or bivalirudin during the surgical procedure.
© 2019 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  abdominal aortic aneurysm; andexanet alfa; direct oral anticoagulants; endovascular aneurysm repair; endovascular repair; factor Xa reversal; rivaroxaban; unfractionated heparin unresponsiveness

Mesh:

Substances:

Year:  2019        PMID: 31251821     DOI: 10.1002/phar.2306

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.

Authors:  Joseph Lewis; Omer Iqbal; Walter Jeske; Debra Hoppensteadt; Fakiha Siddiqui; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

2.  Difficult Intraoperative Heparinization Following Andexanet Alfa Administration.

Authors:  C James Watson; Sara L Zettervall; Matthew M Hall; Michael Ganetsky
Journal:  Clin Pract Cases Emerg Med       Date:  2019-10-14

3.  Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke.

Authors:  Michael Müther; Wolfram Schwindt; Rolf Michael Mesters; Jens Minnerup; Paul Stracke; Markus Holling; Heinz Wiendl; Walter Stummer
Journal:  Neurocrit Care       Date:  2022-08-05       Impact factor: 3.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.